Stockreport

Aimmune's lead candidate successful in late-stage peanut allergy study; shares ahead 19% premarket [Seeking Alpha]

AIMMUNE THERAPEUTICS  (AIMT) 
Last aimmune therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.aimmune.com/corporate-profile
PDF Aimmune's lead candidate successful in late-stage peanut allergy study; shares ahead 19% premarketA 496-subject Phase 3 clinical trial,PALISADE, assessing Aimmune Therap [Read more]